300298 Sinocare Inc.
- 27.76
- +0.64+2.36%
Sinocare Inc. News
Pharmaceutical stocks changed partially. Kyodo Pharmaceutical rose more than 16%, while Qianyuan Pharmaceutical, Yiduoli, Sannuo Biotech, Haier Biotech, and Kazanlian followed suit.
Pharmaceutical stocks changed partially. Kyodo Pharmaceutical rose more than 16%, while Qianyuan Pharmaceutical, Yiduoli, Sannuo Biotech, Haier Biotech, and Kazanlian followed suit.
Sannuo Biotech (300298): Increased R&D investment, CGM accelerates global market expansion
Incident: The company's revenue in 2023 was 4.06 billion yuan (+2.7%), net profit attributable to mother was 280 million yuan (-36.3%), and net profit after deduction of non-return to mother was 290 million yuan (-16.8%). 2024 Q1 Earnings
Sannuo Biotech (300298): The profit side declined slightly year-on-year for the whole year, and CGM is expected to start a second growth curve
Key points: Revenue in 2023 increased 2.69% year on year, and net profit to mother fell 36.31% year on year. Recently, the company released its 2023 annual report and 2024 quarterly report. The company achieved operating income of 40 in 2023
Sannuo Biotech (300298.SZ) has repurchased a total of 3.4215 million shares at a cost of 84.9729 million yuan
Sannuo Biotech (300298.SZ) announced that as of April 30, 2024, the company has passed a share repurchase exclusive...
Sannuo Biotech (300298): Core business performance is in line with expectations, optimistic that CGM will start global expansion
Event: The company released the 2023 annual report and the first quarter report of 2024. The full year of 2023 achieved operating income of 4,059 million yuan (YoY +2.69%) and net profit of 284 million yuan (YoY-3)
Sannuo Biotech (300298): The performance is in line with expectations, the second-generation CGM declared for listing
The 2023 and 1Q24 results are in line with our expectations. The company announced the results for the first quarter of 2023 and 2024: in 2023, the company's revenue was 4.06 billion yuan, up 2.69% year on year; net profit to mother2
Sannuo Biotech (300298) 2023 Report & 2024 Quarterly Report Review: Overseas Subsidiaries' Impairment Affects Apparent Performance, Optimistic CGM Continues to Expand
Summary of key investment points: In 2023, the company achieved operating income of 4,059 billion yuan (2.69%, after adjustment, same ratio, same below), achieved net profit of 284 million yuan (-36.31%), and achieved net income not returned to mother
Huaan Securities released a research report on April 28 stating that it gave Sannuo Biotech (300298.SZ) a purchase rating. The main reasons for the rating include: 1) In the first quarter of 2024, the company achieved revenue of 1,014 million yuan (yoy +1
Huaan Securities released a research report on April 28 stating that it gave Sannuo Biotech (300298.SZ) a purchase rating. The main reasons for the rating include: 1) In the first quarter of 2024, the company achieved revenue of 1,014 million yuan (yoy +14.92%), net profit of 81 million yuan (+35.51%), net profit after deduction of 78 million yuan (yoy +21.48%); 2) the company merged with Trividia in 2023, and impairment calculation affected the company's apparent profit; 3) BGM's main business is stable, and CGM can be expected to expand domestically and internationally. (Mainichi Keizai Shimbun)
Sannuo Biotech (300298) Comment: Dragged down by overseas subsidiaries in 2023 2024Q1 exceeded expectations
Key investment points: Dragged down by subsidiaries in 2023, 2024Q1 performance exceeded expectations: the company released the 2023 annual report and achieved operating income of 4,059 billion yuan in 2023, an increase of 2.7% over the previous year; achieved net profit to mother
Sannuo Biotech (300298): The subsidiary also showed fluctuations in performance and is optimistic about the volume of CGM products
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 4,059 million yuan (+2.69%), net profit attributable to mother of 284 million yuan (-36.31%), after deducting non-net
Sannuo Biotech (300298): Rapid profit growth in 1Q24 is optimistic about full-year performance
The profit side grew rapidly in 1Q24, maintaining that the “buy” rating company achieved revenue/net profit attributable to mother/ net profit of 40.59/2.84/293 million yuan in 23 years (yoy +2.7%/-36.3% /-
Sannuo Biotech (300298.SZ) announced first-quarter results, net profit of 809.376 million yuan, an increase of 35.51% over the previous year
According to Zhitong Finance App, Sannuo Biotech (300298.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 1,014 billion yuan, an increase of 14.92%; net profit attributable to shareholders of listed companies was 809.376 million yuan, an increase of 35.51% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 77.5811 million yuan, an increase of 21.48% year on year; basic earnings per share were 0.1,457 yuan.
Sannuo Biotech (300298) Company Comment: Blood sugar monitoring, steady growth, new product expansion achieved results:
Brief performance review On April 25, 2024, the company released the 2023 annual report and the 2024 first quarter report. In 2023, the company achieved revenue of 4,059 million yuan, +3% year-on-year; net profit to mother was 284 million yuan, year-on-year-
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceu
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceuticals rose more than 5%.
Fu Pengbo, Zhao Feng... Changes in Star Fund Managers' Positions in the First Quarter Revealed
The four funds under Ruiyuan Fund's Ruiyuan Growth Value, Ruiyuan Equilibrium Value for 3 years, Ruiyuan Stable Allocation held for 2 years, and Ruiyuan Wenyi Enhanced 30-day holding all disclosed quarterly reports.
Yao Ming Kangde's decline extended to 2%, and the stock price hit a new low since August 2019. The CRO concept generally declined, with Jiuzhou Pharmaceutical falling more than 8%, and Gloria & Sannuo Biotech falling more than 3%.
Yao Ming Kangde's decline extended to 2%, and the stock price hit a new low since August 2019. The CRO concept generally declined, with Jiuzhou Pharmaceutical falling more than 8%, and Gloria & Sannuo Biotech falling more than 3%.
Sannuo Biotech (300298.SZ) has spent 84.97 million yuan to buy back 3.4215 million shares
According to Zhitong Finance App, Sannuo Biotech (300298.SZ) announced that as of March 31, 2024, the company had repurchased a total of 3.4215 million shares of the company's shares through a special stock repurchase account, accounting for 0.61% of the company's total share capital. The highest transaction price was 26.75 yuan/share, the minimum transaction price was 23.80 yuan/share, and the total transaction amount was 84.97 million yuan.
Sannuo Biotech (300298): Leading domestic blood sugar monitoring company is expected to start a second growth curve
The investment highlights covered Sannuo Biotech (300298) for the first time, with a target price of 27.00 yuan. Based on the segmented valuation method, it corresponds to 34.3 times/28.8 times P/E in 2024/2025.
Sannuo Biotech (300298.SZ): Repurchase 0.61% of shares at a cumulative cost of 84.97.29 million yuan
Gelonghui, March 5, 丨 Sannuo Biotech (300298.SZ) announced that as of February 29, 2024, the company had repurchased 3,421,500 shares of the company's shares through a special stock repurchase account, accounting for 0.61% of the company's total share capital of 564,265,373 shares. The highest transaction price was 26.75 yuan/share, the minimum transaction price was 23.80 yuan/share, and the total transaction amount was 84.97.29 million yuan (excluding transaction fees).
Sannuo Biotech (300298): CGM focusing on blood sugar testing has broken out of the second growth curve
The blood sugar monitoring industry just needs a market and has a large population base. Market potential. Blood sugar monitoring is an important part of diabetes management and treatment. Blood sugar test results can reflect the degree of sugar metabolism disorder in diabetics, and can be used to formulate and evaluate reasonable sugar reduction plans
Analysis
Price Target
No Data
